|Articles|December 1, 2002

December 2002
Volume 8
Issue 12

When Do Developing Countries Adopt Managed Care Policies and Technologies? Part II: Infrastructure, Techniques, and Reform Strategies

Author(s)Jeff Luck, MBA, PhD, John W. Peabody, MD, PhD

Download PDF: When Do Developing Countries Adopt Managed Care Policies and Technologies? Part II: Infrastructure, Techniques, and Reform Strategies

Articles in this issue

over 23 years ago

Article

How Effectively Do Managed Care Organizations Influence Prescribing and Dispensing Decisions?

over 23 years ago

Article

Characteristics of Eye Care Practices With Managed Care Contracts

over 23 years ago

Article

Enhancing the Quality of Care for Patients With Coronary Heart Disease: The Design and Baseline Results of the Hastening the Effective Application of Research Through Technology (HEART) Trail

over 23 years ago

Article

Economic Evaluation of Enoxaparin as Prophylaxis Against Venous Thromboembolism in Seriously Ill Medical Patients: A US Perspective

over 23 years ago

Article

Profiling Resource Use: Do Different Outcomes Affect Assessments of Provider Efficiency?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

When Do Developing Countries Adopt Managed Care Policies and Technologies? Part II: Infrastructure, Techniques, and Reform Strategies

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

When Do Developing Countries Adopt Managed Care Policies and Technologies? Part II: Infrastructure, Techniques, and Reform Strategies

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps

Boston Panel Confronts Access and Coordination Gaps in Obesity Care